Single Biggest Cancer Dictionary in the World
What is KRAS G12D inhibitor INCB161734?
Pronunciation: /kræs ʤi twɛlv di ˌɪnˈhɪbətər incb* wən ˈhənərd ənd sixty-one* ˈθaʊzənd, ˈsɛvən ˈhənərd ənd thirty-four*/
KRAS G12D inhibitor INCB161734
Definition
An orally bioavailable inhibitor of the oncogenic KRAS substitution mutation G12D, with potential antineoplastic activity. Upon oral administration, KRAS G12D inhibitor INCB161734 specifically targets and binds to KRAS G12D. This prevents KRAS G12D-mediated signaling and activation of downstream survival pathways. This leads to an inhibition of the growth of tumor cells that overexpress KRAS G12D. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell proliferation, invasion, and metastasis.